Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The patient received the second dose of RabAvert one month after the first dose; Case reference number US-BN-2025-001194 is a spontaneous case initially received from a healthcare professional via agency (reference number: USBAV25-1698) on 11-Jul-2025 and concerns adult male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 19-Jun-2025, the patient was vaccinated with the first dose of RabAvert along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route, or site of administration, for pre-exposure prophylaxis. On an unspecified date, also reported as one month later, the patient was vaccinated with the second dose of RabAvert along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route, or site of administration (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to RabAvert. No further information was provided.; Reporter's Comments: An adult male patient of unspecified age was vaccinated with the second dose of RabAvert for pre-exposure prophylaxis, reported as one month after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An adult male patient of unspecified age was vaccinated with the second dose of RabAvert for pre-exposure prophylaxis, reported as one month after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE